Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: Confirmatory analysis and research implications

Journal of Affective Disorders

Volumn 114, Issue 1-3, 2009, Pages 143-148

  Smith, Eric G ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antidepressants; Half life; Pediatric; Pharmacokinetics; Suicidal ideation; Suicide attempt

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADOLESCENCE; ARTICLE; BEHAVIOR; CHILD HEALTH CARE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; SUICIDE, ATTEMPTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 59649100537     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.06.018     Document Type: Article

References (26)

1. Angst F., Stassen H.H., Clayton P.J., and Angst J. Mortality for patients with mood disorders: followup over 34-38 years. J. Affect. Disord. 68 (2002) 167-181
2. Brewerton T.D. Fluoxetine-induced suicidality, serotonin, and seasonality. Biol. Psychiatry 30 (1991) 190-196
3. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., and Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297 (2007) 1683-1696
4. Devane C.L., Liston H.L., and Markowitz J.S. Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 41 (2002) 1247-1266
5. Emslie G., Kratochvil C., Vitiello B., Silva S., Mayes T., McNulty S., Weller E., Waslick B., Casat C., Walkup J., Pathak S., Rohde P., Posner K., March J., Columbia Suicidality Classification Group, and TADS Team. Treatment for Adolescents with Depression Study (TADS): safety results. J. Am. Acad. Child Adolesc. Psych. 45 (2006) 1440-1455
6. Findling R.L., McNamara N.K., Stansbrey R.J., Feeny N.C., Young C.M., Peric F.V., and Youngstrom E.A. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J. Child. Adolesc. Psychopharmacol. 16 (2006) 131-145
7. Gibbons R.D., Hendricks Brown C., Hur K., Marcus S.M., Bhaumik D.K., and Mann J.J. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am. J. Psychiatry 164 (2007) 1044-1049
8. Gunnell D., Saperia J., and Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 330 (2005) 385-388
9. Hammad T.A. Relationship Between Psychotropic Drugs and Pediatric Suicidality. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee Web site (2004). http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed on October 31, 2006
10. Hammad T.A., Laughren T., and Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry. 63 (2006) 332-339
11. Lambert G.W., Reid C., Kaye D.M., Jennings G.L., and Esler M.D. Effect of sunlight and season on serotonin turnover in the brain. Lancet 360 (2002) 1840-1842
12. Lambert G.W., Reid C., Kaye D.M., Jennings G.L., and Esler M.D. Increased suicide rate in the middle-aged and its association with hours of sunlight. Am. J. Psychiatry 160 (2003) 793-795
13. Laughren T.P. Background Comments for February 2, 2004 Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee (Peds AC) (2004). http://www.fda.gov/OHRMS/DOCKETS/ac/04/briefing/4006B1_03_Background%20Memo%2001-05-04.pdf www.fda.gov/OHRMS/DOCKETS/ac/04/briefing/4006B1_03_Background%20Memo%2001-05-04.pdf. Accessed May 20, 2007.
14. Leon A.C., Marzuk P.M., Tardiff K., Bucciarelli A., Markham Piper T., and Galea S. Antidepressants and youth suicide in New York City, 1999-2002. J. Am. Acad. Child Adolesc. Psych. 45 (2006) 1054-1058
15. March J.S., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., Burns B., Domino M., McNutly S., Vitiello B., and Severe J. Treatment for Adolescents with depression study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 292 (2004) 807-820
16. Physician's Desk Reference, 62nd Edition (2008) Montvale, NJ: Medical Economics Co.
17. Posner K., Oquendo M.A., Gould M., Stanley B., and Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am. J. Psychiatry 164 (2007) 1035-1043
18. Rothschild A.J., and Locke C.A. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J. Clin. Psychiatry. 52 (1991) 491-493
19. Saperia J., Ashby D., and Gunnell D. Suicidal behaviour and SSRIs: updated meta-analysis. BMJ 332 (2006) 1453
20. SPSS for Windows version 14.0. Copyright 2005. (SPSS, Inc: Chicago, IL, USA).
21. Sondergard L., Kvist K., Andersen P.K., and Kessing L.V. Do antidepressants prevent suicide?. Int. Clin. Psychopharmacol. 21 (2006) 211-218
22. Stone M.B., and Jones M.L. FDA Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults (2006). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf November 17, 2006. pp. 1-65. Available at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf. Accessed July 22, 2007.
23. Teicher M.H., Glod C.A., and Cole J.O. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry. 147 (1990) 207-210
24. Teicher M.H., Glod C.A., and Cole J.O. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 8 (1993) 186-212
25. Weiss J.J., and Gorman J.M. Antidepressant adherence and suicide risk in depressed youth. Am. J. Psychiatry 162 (2005) 1756-1757
26. www.rxlist.com. Information for fluvoxamine and mirtazapine half-lives listed under "Clinical Pharmacology". Accessed on November 2, 2006.